These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22485076)

  • 21. Treatment of chronic hepatitis C: current and future.
    Pawlotsky JM
    Curr Top Microbiol Immunol; 2013; 369():321-42. PubMed ID: 23463207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
    Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z;
    Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New antiviral therapies in the management of HCV infection.
    Farnik H; Zeuzem S
    Antivir Ther; 2012; 17(5):771-83. PubMed ID: 22626842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
    Welsch C; Jesudian A; Zeuzem S; Jacobson I
    Gut; 2012 May; 61 Suppl 1():i36-46. PubMed ID: 22504918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
    Foote BS; Spooner LM; Belliveau PP
    Ann Pharmacother; 2011 Sep; 45(9):1085-93. PubMed ID: 21828346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of hepatitis C: current status and perspectives].
    Pol S; Corouge M
    Rev Prat; 2014 May; 64(5):605-12. PubMed ID: 24923038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.
    Perry CM
    Drugs; 2012 Mar; 72(5):619-41. PubMed ID: 22439668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New HCV therapies on the horizon.
    Vermehren J; Sarrazin C
    Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Boceprevir: a protease inhibitor for the treatment of hepatitis C.
    Chang MH; Gordon LA; Fung HB
    Clin Ther; 2012 Oct; 34(10):2021-38. PubMed ID: 22975763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
    Matthews SJ; Lancaster JW
    Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.
    Garnock-Jones KP
    Drugs; 2012 Dec; 72(18):2431-56. PubMed ID: 23231027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents.
    Kamal SM
    Hepat Med; 2014; 6():61-77. PubMed ID: 25114601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel drugs in the management of difficult-to-treat hepatitis C genotypes.
    Cartwright EJ; Miller L
    Hepat Med; 2013; 5():53-61. PubMed ID: 24696624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Telaprevir: changing the standard of care of chronic hepatitis C.
    Rajani AK; Ravindra BK; Dkhar SA
    J Postgrad Med; 2013; 59(1):42-7. PubMed ID: 23525057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding the molecular targets for new therapeutical agents in hepatitis c infection.
    Vagu C; Sultana C; Ruţă S
    Roum Arch Microbiol Immunol; 2013; 72(1):5-24. PubMed ID: 23947011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection.
    Kanda T; Nakamoto S; Nakamura M; Jiang X; Miyamura T; Wu S; Yokosuka O
    J Clin Transl Hepatol; 2014 Mar; 2(1):1-6. PubMed ID: 26356295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.
    Klibanov OM; Vickery SB; Olin JL; Smith LS; Williams SH
    Pharmacotherapy; 2012 Feb; 32(2):173-90. PubMed ID: 22392426
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.